pharma · Hypertriglyceridemia · Type 2 Diabetes Mellitus · IONS
IONIS PHARMACEUTICALS INC
IONIS PHARMACEUTICALS drug portfolio — 32 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 32 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
IONIS PHARMACEUTICALS drug portfolio — 32 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
US regulatory status: approved.
US regulatory status: approved. Mechanism: Serotonin 2a (5-HT2a) receptor antagonist.
US regulatory status: approved.
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
US regulatory status: approved. Mechanism: Unknown.
Antiinfectives for systemic use (J07) compound in IONIS PHARMACEUTICALS's portfolio.
Blood and blood forming organs (B06) compound in IONIS PHARMACEUTICALS's portfolio.
US regulatory status: approved.
Nervous system (N07) compound in IONIS PHARMACEUTICALS's portfolio. Molecular target: Transthyretin mRNA.
US regulatory status: approved. Molecular target: Transthyretin mRNA.
US regulatory status: approved. Molecular target: Estrogen receptor.
Sensory organs (S01) compound in IONIS PHARMACEUTICALS's portfolio. Molecular target: Major intermediate early region 2 mRNA.
US regulatory status: approved. Molecular target: Major intermediate early region 2 mRNA.
Antiinfectives for systemic use (J07) compound in IONIS PHARMACEUTICALS's portfolio. Molecular target: Surface antigen (HBsAg).
Nervous system (N07) compound in IONIS PHARMACEUTICALS's portfolio. Mechanism: Transthyretin ANTISENSE inhibitor.
US regulatory status: approved. Molecular target: Transthyretin mRNA.
US regulatory status: approved. Molecular target: Cyclooxygenase.
Development asset linked to IONIS PHARMACEUTICALS in public FDA and regional records.
US regulatory status: approved. Molecular target: Apo-B 100 mRNA.
Cardiovascular system (C10) compound in IONIS PHARMACEUTICALS's portfolio. Molecular target: Apolipoprotein C-III mRNA.
US regulatory status: approved.
US regulatory status: approved. Mechanism: Unknown.
US regulatory status: approved. Molecular target: Copper.
US regulatory status: approved. Molecular target: Inosine-5'-monophosphate dehydrogenase 1.
US regulatory status: approved.
Musculo-skeletal system (M09) compound in IONIS PHARMACEUTICALS's portfolio. Mechanism: Somatic cell supplemental therapy.
US regulatory status: approved. Molecular target: SOD1 mRNA.
Cardiovascular system (C10) compound in IONIS PHARMACEUTICALS's portfolio. Mechanism: Apolipoprotein C-III mRNA 3'UTR antisense inhibitor.
Development asset linked to IONIS PHARMACEUTICALS in public FDA and regional records. Mechanism: Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor.
US regulatory status: approved. Molecular target: Vitamin K epoxide reductase complex subunit 1.